Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

Gilead Sciences, in partnership with the Global Fund, plans to supply a long-acting HIV prevention drug to low-income ...

C ongress just passed a sweeping bill that includes changes to Medicaid expected to cut millions of people with low incomes ...

Global Fund aims for the first shipment to reach at least one African country by year-end. Read more at straitstimes.com.

A secondary analysis of a large trial shows that exposure to the HIV drug abacavir is linked to an elevated risk for major ...

The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. But ...

The results expose a striking prevalence of high-risk sexual behaviours. Over one-third of participants (34.0%) disclosed ...

Is the cost of research aimed at curing HIV worth it, when HIV can be effectively managed and prevented by existing drugs?

People living with HIV face unique oral health challenges that require special attention and care. The virus's impact on the ...

COVID paused prevention efforts, which helped fuel the rise in new infections. Now federal funding cuts threaten to disrupt ...